26 April 2022 – Directorate Change

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Directorate Change

Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from his position as Chairman, at the Company’s next Annual General Meeting (“AGM”). The Board is pleased to confirm that he will remain on the Board as a Non-executive Director.

Dr John Brown CBE, currently a Non-executive Director of the Company and its Senior Independent Director, will assume the role of Chairman of the Group from the same date.

Adam Reynolds has been instrumental in transforming the Company in his five years of service as Chairman, and before that as a Non-executive Director, overseeing key hires on the senior leadership team, rebuilding and navigating the Company post litigation and guiding Yourgene through several successful acquisitions, all contributing to the Group recording record revenue growth, sustaining a step change in financial performance and creating a broader offering of products and services. In the coming months Adam will ensure an orderly handover and transition to a Non-executive Director role.

Dr John Brown joined the Board of Yourgene on 29 July 2019 as a Non-executive Director and has acted as Senior Independent Director to the Company. Dr Brown has over 20 years’ capital markets experience in the healthcare and life sciences sector. He is currently a Senior Independent Director of Acacia Pharma and is Chairman of Calcivis. Additionally, he has previous significant board experience with roles including Chairman of Axis-Shield, BTG and Cell Therapy Catapult, Non-executive Director of Vectura and Chief Executive Officer of Acambis.

Adam Reynolds, outgoing Chairman of Yourgene, said: “As we embark on the next phase of Yourgene’s journey  we have a very strong successor in Dr  John Brown as Chairman. I will remain on the Board as a supportive NED and shareholder and I remain as convinced as ever in the prospects for Yourgene Health.”

Lyn Rees, CEO of Yourgene, said: “I would like to thank Adam for his support and contribution to Yourgene, as the Group has transformed into the business it is today. Adam has been instrumental in overseeing the growth we have achieved and we are pleased that we can retain his extensive experience and knowledge as he remains a supportive NED.

“We are thrilled Dr John Brown is becoming the Group’s Chairman, a testament to Yourgene attracting such a high calibre and experienced Chair, who has been able to get to know the business over the last couple of years whilst in his current NED role. The breadth of capital markets experience in the healthcare sector Dr Brown can offer Yourgene is paramount as the Group enters its next stage of growth and development.”  

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122


Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti
 Tel: +44 (0)20 7213 0880
Singer Capital Markets (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas
Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Applegarth / Alice Woodings

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 Mob: 07584 391 303 Mob: 07407 804 654

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.